ALK announces acquisition of Bio-Medical Services ALK.

Since 1923, ALK provides exemplified scientific leadership in the field of allergy analysis, and has remained focused on the treatment of allergic disease in human beings. Bio-Medical Services introduced in vitro serum IgE allergy tests to the veterinary market in 1989, and has a proven background for treating allergic disease for canines, cats and horses. With this acquisition, ALK is now positioned to increase its allergy focus to include the very important veterinary allergy marketplace. Related StoriesMajority of individuals not allergic to intravenous penicillins, state ACAAI allergistsInternational research study examines effectiveness of proven medications for different diseasesGastric decrease surgery can significantly increase patient's threat of developing allergy ‘Joining forces with ALK will allow us to supply complete allergy management resources to veterinary dermatologists and general practitioners as well.1, 2009 through Sept. 30, 2010, includes increases of $295.2 million in budget authority and $215.4 million in industry user charges. The FDA budget proposes two main initiatives for FY 2010: Protecting America’s Food Supply and Safer Medical Products. It also includes boosts for current law consumer costs and for infrastructure to support critical agency functions. The FDA is also proposing four new consumer fees to facilitate review of generic drugs, register and inspect food manufacturing and processing facilities, reinspect facilities that fail to meet Great Manufacturing Practices and additional safety requirements, and concern export certifications for food and feed. This historic upsurge in the FDA’s spending budget is a superb investment in public wellness, said Joshua Sharfstein, M.D., Performing Commissioner of Drugs and Food.